Pharmacokinetics of Continuous Infusion Beta-Lactams in the Treatment of Acute Pulmonary Exacerbations in Adult Cystic Fibrosis Patients.
Hong LT , Liou TG , Deka R , King JB , Stevens V , Young DC 
Chest.2018 Jun 13 ; ():.
PubMedで表示
Google翻訳で開く
(24view , 0users)
Several clinical trials have demonstrated the efficacy of continuous infusion (CI) beta-lactam (BL) antibiotics in cystic fibrosis (CF) patients; however, little is known regarding pharmacokinetic changes during treatment of an acute pulmonary exacerbation (APE). Identifying and understanding these changes may assist in optimizing antibiotic dosing during APE treatment.
PMID: 29908155 [PubMed - as supplied by publisher]
PMID: 29908155 [PubMed - as supplied by publisher]
関連論文
- Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis.
- Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.
- Tobramycin and Beta-Lactam Antibiotic Use in Cystic Fibrosis Exacerbations: A Pharmacist Approach.
- Safety of intravenous tobramycin in combination with a variety of anti-pseudomonal antibiotics in children with cystic fibrosis.